TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00989729
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single preoperative dosage 30 mg/kg Methylprednisolone suspended in physiological saline (100 ml in total) given intravenously as a 30 minute infusion, 2 hours before surgery.
Study: NCT02304042
Drug: Carbetocin
Normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin will be given slowly iv after delivery of the anterior shoulder.
Study: NCT02304042
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin will be given slowly iv after delivery of the anterior shoulder.
Study: NCT00548808
Drug: Insulin lispro low mixture
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose depending on patient's need; subcutaneous injection before meal; start with once-daily injection before evening meal for 48 weeks, may add second injection before breakfast at any time during the treatment period if required, and may further add third injection before lunch at any time in the remainder of the treatment period if required.
Study: NCT00548808
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose depending on patient's need; one daily subcutaneous injection before bedtime for 48 weeks
Study: NCT00000191
Drug: Carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00548808
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose depending on patient's need; subcutaneous injection before meal; may start once-daily injection before meal (e.g. lunch if the highest blood glucose value is measured before dinner) on top of insulin glargine at any time of the treatment period if required, and may further add second or even third injection in the remainder of the treatment period if required.
Study: NCT03218722
Drug: Pro-Thrombin Concentrate Complex
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg PCC.
Study: NCT00428545
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting Dose 2.5 mg/kg By Vein On Day 1 Every 21 Days
Study: NCT00428545
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting Dose 0.7 mg/m\^2 By Vein On Days 1 and 8 Every 21 Days
Study: NCT00501540
Drug: Lithium Carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium 300mg PO TID escalating to a lithium level of 0.8-1.2. Lithium carbonate will be administered the first week at 300 mg flat dose three times each day. A serum lithium level will be checked after 4-5 days of treatment by drawing a blood sample prior to the morning dose of lithium. Evaluate every 8 weeks.
Study: NCT00054613
Drug: Methoxsalen
Normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04330079
Drug: Dapagliflozin 10mg
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10mg once daily for 6 months.
Study: NCT01532687
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01532687
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01532687
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT01532687
Drug: Pazopanib Hydrochloride
Normalized name: Pazopanib Hydrochloride
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT03844191
Drug: RUC-4 Compound
Normalized name: Blackburn Compound
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single subcutaneous administration of RUC-4
Study: NCT04502771
Drug: Antifungal treatment
Normalized name: TOLNAFTATE 10 mg in 1 mL TOPICAL LIQUID [Liquid Antifungal Treatment]
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment by fluconazole, voriconazole,posaconazole or caspofungin during the patient stay in Intensive Care Unit
Study: NCT03424681
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 300 mg by mouth daily
Study: NCT02809976
Drug: Ruxolitinib 1.5% Phosphate Cream
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: twice daily topical application of Ruxolitinib 1.5% Phosphate Cream beginning at baseline and ending at week 20
Study: NCT00134368
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00388687
Drug: 18F Fluoroazomycin Arabinoside (FAZA)
Normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01704339
Drug: QUTENZA
Normalized name: Qutenza
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single treatment with topical capsaicin 8%
Study: NCT04307186
Drug: Gadobutrol (Gadovist/Gadavist)
Normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution for IV injection, single dose
Study: NCT02106468
Drug: Prednisone tablet 5mg
Normalized name: prednisone Oral Tablet
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This group included 15 patients who received prednisone (Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening) for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.
Study: NCT02640794
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months.
Study: NCT02640794
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin/acetylsalicylic acid (80-325 mg/d). Aspirin/acetylsalicylic acid therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
Study: NCT04394351
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-use, prefilled syringe
Study: NCT00828646
Drug: BMS-708163
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, Oral, 50 mg, once daily, 14 days
Study: NCT00828646
Drug: BMS-708163
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, Oral, 100 mg/day, once daily, 14 days
Study: NCT00828646
Drug: BMS-708163
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, Oral, 75 or 100 mg/day, once daily, 14 days
Study: NCT00824317
Drug: methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (15 mg daily), medium (25 mg daily) and high (40 mg daily)
Study: NCT00058240
Drug: alvocidib
Normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01068327
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01068327
Drug: nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00967408
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rehabilitative treatment + Oral Escitalopram 5 mg/day for the first week, 10 mg/day from second to fourth week and 20 mg/day until 6th month.
Study: NCT01114841
Drug: Tazarotene Foam
Normalized name: tazarotene Topical Foam
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patches containing Tazarotene Foam 0.1% will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.~There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).~These patches will then be evaluated at 24, 48, and 72 hours.~There may be a second rest period and a second 48-hour patch application and evaluation, if required.
Study: NCT01114841
Drug: Vehicle Foam
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patches containing Vehicle Foam will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.~There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).~These patches will then be evaluated at 24, 48, and 72 hours.~There may be a second rest period and a second 48-hour patch application and evaluation, if required.
Study: NCT00647712
Drug: Divalproex Sodium Extended-Release Tablets 500 mg
Normalized name: divalproex sodium Extended Release Oral Tablet
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500mg, single dose fasting
Study: NCT02732847
Drug: Usual Dated
Normalized name: Date
DrugBank: Date (DB10632)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01826149
Drug: Propofol 1.0mcg
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol dosage titration to achieve effect site concnetration at 1.0 mcg/ml using target controlled infusion.
Study: NCT01826149
Drug: Propofol 2.0mcg
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol dosage titration to achieve effect site concnetration at 2.0 mcg/ml using target controlled infusion.
Study: NCT01826149
Drug: Propofol 3.0mcg
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol dosage titration to achieve effect site concnetration at 3.0 mcg/ml using target controlled infusion
Study: NCT02483247
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes on day 1 and day 15 of each 28 day cycle.
Study: NCT02483247
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every three weeks (21-days).
Study: NCT02483247
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg/m\^2 body surface area is administered intravenously once weekly on day 1, day 8, and day 15 of each 28 day cycle.
Study: NCT02483247
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib 37.5 mg is administered once daily.
Study: NCT02238535
Drug: Ventavis
Normalized name: Ventavis
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02238535
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02992899
Drug: O-15 water
Normalized name: water, O-15
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen-15 labelled water is a radioactive variation of regular water, in which the oxygen atom has been replaced by oxygen-15 (15O), a positron-emitting isotope. 15O-water is used as a radioactive tracer for measuring and quantifying blood flow using positron emission tomography (PET) . H2\[15O\] will be prepared on-site in the Emory PET Center cyclotron. During the hours of the test, an intravenous infusion of normal saline will be started to permit the bolus injection of H2\[15O\]. Subjects will receive a 20 mCi intravenous bolus of H2\[15O\] for each of the 14 scans during exposure to neutral and traumatic scripts.
Study: NCT01590823
Drug: Dabigatran Etexilate 110 mg
Normalized name: dabigatran etexilate 110 MG
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will receive a single dosage of dabigatran etexilate 110 mg at the start of their 4 hour dialysis session. Blood sampling will be conducted during and up to 48 hours after participant's dialysis session.
Study: NCT01284647
Drug: Teprenone capsule and placebo of sucralfate
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Teprenone 1 capsule (50mg)+placebo of sucralfate 4tab, tid×8 weeks.
Study: NCT01284647
Drug: Sucralfate and placebo of teprenone
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo of teprenone 1 capsule+ sucralfate 4 tab(1.0), tid×8 weeks
Study: NCT01942382
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive 4 injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in deltoid or gluteal muscle as randomized to treatment group A, B, or C on Days 1, 8, 36, and 64.
Study: NCT04745143
Drug: NMDAE
Normalized name: NMDA
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of an NMDA enhancer for the treatment of schizophrenia
Study: NCT03228238
Drug: Vitamin C and Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid Tablet 1g and Tocopherol Capsule 400IU
Study: NCT01018264
Drug: solifenacin succinate (VESIcare)
Normalized name: solifenacin succinate Oral Tablet [Vesicare]
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: up to 10mg every day orally
Study: NCT06360588
Drug: Copanlisib
Normalized name: Copanlisib
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02002767
Drug: Velpatasvir
Normalized name: Velpatasvir
DrugBank: Velpatasvir (DB11613)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Velpatasvir 100 mg (2 x 50 mg tablets) administered orally
Study: NCT01158222
Drug: sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally
Study: NCT01280929
Drug: Intravitreous injection of ranibizumab
Normalized name: ranibizumab Injection
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03388814
Drug: Local infiltration of bupivacaine
Normalized name: Esters of aminobenzoic acid for local anesthesia
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients assigned to the local infiltration with bupivacaine group will receive 30 ml of 0.25% bupivacaine with 1:200,000 epinephrine. These injections will occur at the end of the mastectomy and prior to the insertion of the tissue expander implant. The local anesthetic will be injected into the chest wall and skin flaps. Attending physicians and resident physicians will receive prior instruction regarding correct placement of the local anesthetic so that it will be consistently placed in the same locations with similar volume distribution.
Study: NCT03388814
Drug: Pectoralis Nerve block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients assigned to the pectoralis block group will receive a total of 20 ml 0.25% bupivacaine (with 1:200,000 epinephrine and 1.67 mcg clonidine per ml) in the tissue plane between the serratus anterior and the pectoralis minor muscles at approximately the level of the 4th rib and 10 ml of the same solution in the tissue plane between the two pectoralis muscles at approximately the 3rd rib under ultrasound guidance on the surgical side preoperatively.
Study: NCT04416035
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered at an AUC 6 mg/mL/ min (the maximum dose capped at 900 mg) by IV infusion (over 15 - 30 minutes) Q3W on Day 1 of each cycle.
Study: NCT04416035
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered at a dose of 200 mg/m\^2 by IV infusion (over 3 hours) Q3W on Day 1 of each cycle
Study: NCT01105247
Drug: PCI-32765
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 420 mg daily or 840 mg daily
Study: NCT01159301
Drug: entinostat
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally (PO)
Study: NCT01159301
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00002884
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02100007
Drug: ME-344
Normalized name: ME-344
DrugBank: ME-344 (DB13062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: ME-344 IV at 10 mg/kg on Days 1, 8, 15, and 22 of each 28-day cycle. Part 2: ME-344 IV at the dose defined in Part 1 on Days 1, 8, 15, and 22 of each 28 day cycle.~Patients will be allowed to continue receiving ME-344 infusions weekly according to the assigned dose level as long as there is clinical benefit to the patient as assessed by the Investigator.
Study: NCT02100007
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part 1: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle. Part 2: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle.
Study: NCT01859715
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects given oxycodone 5mg by ED provider decision or by triage nurse randomization.
Study: NCT01859715
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects given ondansetron 4mg for reported nausea or vomiting. Treatment determined either by triage nursing protocol or by provider discretion. Observational intervention only.
Study: NCT01046916
Drug: TAK-700
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-700 will be administered orally (PO) twice daily (BID) on a continuous schedule
Study: NCT01427205
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Loading dose 400 mg/m2 by vein once followed by 250 mg/m2 weekly (+/- 7 days).
Study: NCT01427205
Drug: OSI-906
Normalized name: OSI-461
DrugBank: OSI-461 (DB05415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg by mouth twice a day.
Study: NCT02953834
Drug: kisspeptin 112-121
Normalized name: Kisspeptin
DrugBank: Kisspeptin (DB19112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 0.313-12.5 mcg/kg Duration: up to 16 hours
Study: NCT01978431
Drug: cocaine hydrochloride
Normalized name: Cocaine Hydrochloride
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01978431
Drug: methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02621970
Drug: Cisplatin 1
Normalized name: cisplatin 1 MG/ML
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 25 mg/m2, D1-3
Study: NCT02621970
Drug: Cisplatin 2
Normalized name: CISPLATIN 200MG/VIL (PF) INJ
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2, D1
Study: NCT02621970
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60mg/m2, D1
Study: NCT02621970
Drug: Xeloda
Normalized name: Xeloda
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Xeloda 2000mg/m2, D1-14 in concurrent chemotherapy and Xeloda 2500mg/m2, D1-14 in adjuvant chemotherapy
Study: NCT00128180
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone 16 mg/kg/day for 3 days as follows: 8 mg/kg (up to 500 mg) given over first hour followed by 8 mg/kg over the next 23 hours; then 16 mg/kg (up to 1000 mg) on days 2 and 3 administered over 24 hours.
Study: NCT01173562
Drug: Mebendazole
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Type= exact number, unit= mg, number= 500, form= chewable tablet, route= oral use. One mebendazole 500-mg chewable tablet taken on Day 1.
Study: NCT04394728
Drug: Trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.3 mg/m2 with a top-dose of 2.6 mg per cycle, via a central venous catheter as a 24-hour infusion every 21 days.All patients received premedication with dexamethasone 20 mg i.v. 30 min before administration of trabectedin.
Study: NCT00191893
Drug: teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00724451
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin administered in accordance with approved labeling
Study: NCT05337878
Drug: Pelacarsen
Normalized name: Pelacarsen
DrugBank: Pelacarsen (DB16284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelacarsen administered by SC injection.
Study: NCT00317681
Drug: Tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01584947
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine lozenge taken 3 times a day for two weeks